VRTX Vertex Pharmaceuticals Incorporated Stock Quote

VRTX [NASD]

Index	S&P 500	P/E	20.23	EPS (ttm)	10.30	Insider Own	0.20%	Shs Outstand	259.96M	Perf Week	-3.96%
Market Cap	54.30B	Forward P/E	16.08	EPS next Y	12.96	Insider Trans	-13.32%	Shs Float	259.34M	Perf Month	-10.07%
Income	2.71B	PEG	1.10	EPS next Q	2.70	Inst Own	94.40%	Short Float	1.54%	Perf Quarter	-8.48%
Sales	6.21B	P/S	8.75	EPS this Y	128.00%	Inst Trans	-1.39%	Short Ratio	2.05	Perf Half Y	-25.32%
Book/sh	33.61	P/B	6.20	EPS next Y	14.67%	ROA	25.70%	Target Price	284.73	Perf Year	-8.68%
Cash/sh	25.56	P/C	8.15	EPS next 5Y	18.33%	ROE	35.20%	52W Range	197.47 - 306.08	Perf YTD	-11.81%
Dividend	-	P/FCF	18.14	EPS past 5Y	45.30%	ROI	26.40%	52W High	-32.11%	Beta	0.62
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	43.20%	Gross Margin	88.10%	52W Low	5.23%	ATR	6.06
Employees	3400	Current Ratio	4.30	Sales Q/Q	15.20%	Oper. Margin	46.00%	RSI (14)	39.39	Volatility	2.41% 2.66%
Optionable	Yes	Debt/Eq	0.07	EPS Q/Q	3.90%	Profit Margin	43.70%	Rel Volume	1.16	Prev Close	208.44
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Feb 01 AMC	Payout	0.00%	Avg Volume	1.95M	Price	207.79
Recom	1.80	SMA20	-2.26%	SMA50	-7.39%	SMA200	-17.11%	Volume	2,254,967	Change	-0.31%

Feb-23-21

Upgrade

Robert W. Baird

Neutral → Outperform

$220 → $252

Feb-02-21

Reiterated

H.C. Wainwright

Buy

$315 → $275

Dec-30-20

Initiated

Daiwa Securities

Outperform

$250

Nov-30-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$247 → $267

Nov-20-20

Initiated

Bernstein

Outperform

$225

Oct-28-20

Initiated

UBS

Buy

$287

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$295 → $315

Jul-08-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$300

Apr-30-20

Reiterated

H.C. Wainwright

Buy

$270 → $295

Apr-28-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$250 → $260

Mar-04-20

Initiated

Barclays

Overweight

$271

Jan-31-20

Downgrade

Robert W. Baird

Outperform → Neutral

$210 → $230

Nov-19-19

Upgrade

Guggenheim

Neutral → Buy

$252

Nov-12-19

Initiated

SunTrust

Buy

$235

Oct-17-19

Resumed

BofA/Merrill

Buy

$220

Sep-03-19

Upgrade

Goldman

Neutral → Buy

$226 → $254

Aug-01-19

Downgrade

Needham

Buy → Hold

May-23-19

Resumed

Citigroup

Buy

$205

May-21-19

Initiated

Credit Suisse

Outperform

$209

Apr-12-19

Initiated

Evercore ISI

In-line

Mar-03-21 11:30AM	Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? Zacks
Mar-02-21 05:51AM	3 Growth Stocks That'll Make You Richer in March (and Beyond) Motley Fool
Feb-24-21 09:01AM	Vertex to Present at the Cowen Health Care Conference on March 2 Business Wire
Feb-21-21 06:36AM	Forget Bitcoin: 4 Stocks to Buy Hand Over Fist Instead Motley Fool
Feb-20-21 07:10AM	What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash? Motley Fool
Feb-19-21 07:50AM	Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared Motley Fool
Feb-18-21 12:49PM	Is Vertex Pharmaceuticals (VRTX) Stock a Buy For 2021? Insider Monkey
Feb-17-21 02:00PM	Here's What Caused Royalty Pharma's Mixed Results in Q4 Motley Fool
08:19AM	Wall Street Looks Again at Bluebird, Rivals, After Gene-Therapy Setback Barrons.com
Feb-15-21 06:22AM	3 Healthcare Stocks I'd Buy Right Now Motley Fool
Feb-14-21 05:51AM	5 Sizzling Growth Stocks to Buy for a Biden Bull Market Motley Fool
Feb-11-21 08:53AM	Should You Take Comfort From Insider Transactions At Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Simply Wall St.
Feb-06-21 05:36PM	Top 10 Large-Cap Healthcare Stocks to Buy Now Insider Monkey
Feb-05-21 09:32AM	CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? Zacks
07:55AM	3 Reasons It's Not Too Late to Buy Vertex Pharmaceuticals Motley Fool
Feb-03-21 10:25AM	Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More Zacks
06:10AM	Ignore GameStop: Here Are 3 Better Stocks Motley Fool
Feb-02-21 04:35PM	Why Vertex Pharmaceuticals Stock Fell Today Motley Fool -6.23%
10:26AM	Vertex CEO says company is seeking to make 'transformative' deals MarketWatch
10:25AM	Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates Zacks
06:03AM	Why Vertex Pharmaceuticals' Solid Q4 Results Weren't Good Enough Motley Fool
Feb-01-21 10:30PM	Vertex Pharmaceuticals Inc (VRTX) Q4 2020 Earnings Call Transcript Motley Fool
05:56PM	Markets Snap Back into Bullish Territory Zacks
05:25PM	Vertex Pharmaceuticals (VRTX) Lags Q4 Earnings Estimates Zacks
04:53PM	Vertex Stock Dips On Mixed Report; Investors Eye Its Next Catalysts Investor's Business Daily
04:39PM	Vertex Pharmaceuticals: Q4 Earnings Insights Benzinga
04:01PM	Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results Business Wire
02:30PM	Vertex Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
06:06AM	3 Top Stocks That'll Make You Richer in February (and Beyond) Motley Fool
05:43AM	Zacks.com featured highlights include: Crocs, AGCO, Meritage Homes and Vertex Pharmaceuticals Zacks
Jan-31-21 03:58AM	Earnings to Watch Next Week: Pfizer, Alibaba, Amazon, Alphabet and Qualcomm in Focus FX Empire
Jan-30-21 01:19PM	The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga
Jan-29-21 10:12AM	Earnings Preview for Vertex Pharmaceuticals Benzinga
09:39AM	Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings? Zacks
09:31AM	Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance Zacks
08:44AM	Why Earnings Season Could Be Great for Vertex (VRTX) Zacks
08:22AM	4 Stocks That Flaunt an Impressive Interest Coverage Ratio Zacks
07:45AM	The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga
06:12AM	3 Top Healthcare Stocks to Buy Right Now Motley Fool
Jan-28-21 04:11PM	Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D) Business Wire
08:42AM	Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings? Zacks
Jan-27-21 11:13AM	Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA Zacks -5.21%
11:05AM	Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates Zacks
Jan-26-21 09:40AM	The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna Zacks
08:30AM	Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations Business Wire
Jan-25-21 05:45PM	Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Zacks
03:45PM	Top Stock Reports for NIKE, Amgen & Morgan Stanley Zacks
12:30PM	Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
06:01AM	Why I'm Betting Big on This 1 Megatrend Motley Fool
Jan-24-21 07:10AM	Where to Invest $1 Million Right Now Motley Fool
Jan-22-21 09:01AM	Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1 Business Wire
05:51AM	Got $4,000? 4 Game-Changing Stocks to Buy in 2021 Motley Fool
Jan-21-21 12:10PM	Why the Earnings Surprise Streak Could Continue for Vertex (VRTX) Zacks
Jan-20-21 08:23AM	The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics Zacks
Jan-19-21 10:46AM	CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why Zacks
Jan-18-21 08:03AM	5 Stocks Expected to Crush the S&P 500 Investopedia
Jan-15-21 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Moves -0.25%: What You Should Know Zacks
Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals Zacks
Jan-10-21 07:05AM	The Top 3 Biotech Stocks to Buy in 2021 Motley Fool
06:06AM	3 Top Biotech Picks for 2021 Motley Fool
Jan-08-21 05:45PM	Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Zacks
Jan-07-21 09:01AM	Vertex to Present at the J.P. Morgan Healthcare Conference on January 11 Business Wire
07:00AM	Where to Invest $100,000 Right Now Motley Fool
Jan-06-21 06:25AM	Expecting a $600 Stimulus Check? These 2 Stocks Should Rebound Big Motley Fool
Jan-05-21 07:08AM	3 Recession-Proof Healthcare Stocks to Buy for 2021 Motley Fool
06:36AM	3 Nasdaq 100 Stocks That Can Make You a Boatload of Money in 2021 Motley Fool
06:00AM	Get Ready for Health-Care Stocks to Go Wild. How to Play Them. Barrons.com
Jan-04-21 09:30AM	Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study Zacks
Jan-03-21 10:13PM	Why The EPS Rating Is One Key To Picking The Best Stocks Investor's Business Daily
Jan-01-21 06:36AM	4 Unstoppable Stocks to Buy for a Biden Bull Market in 2021 Motley Fool
Dec-31-20 08:49AM	Arcturus (ARCT) to Develop ARCT-032 for Cystic Fibrosis Zacks
Dec-30-20 08:41AM	Is Vertex Pharmaceuticals (VRTX) a Smart Long-term Buy? Insider Monkey
Dec-29-20 07:57AM	Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 38% Discount? Simply Wall St.
Dec-28-20 08:04AM	Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada Business Wire
Dec-27-20 07:31AM	The 3 Best Healthcare Stocks to Buy for 2021 Motley Fool
Dec-26-20 05:51AM	3 Surefire Stocks to Buy With Your $600 Stimulus Check Motley Fool
Dec-24-20 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
07:02AM	Where to Invest $5,000 Right Now Motley Fool
06:45AM	The 3 Best Stocks for 2021 Motley Fool
Dec-23-20 10:09AM	Vertex (VRTX) Inks Deal with Skyhawk for Serious Diseases Zacks
06:06AM	3 Beaten-Down Growth Stocks That Can Soar in 2021 Motley Fool
Dec-22-20 12:56PM	4 Biopharma Stock Picks From Analysts for 2021 Barrons.com
11:42AM	Vertex Pharmaceuticals Enters New Partnership With RNA Expert Skyhawk Therapeutics Motley Fool
08:30AM	Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases Business Wire
Dec-21-20 04:24PM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives Investor's Business Daily
02:30PM	Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations Business Wire
Dec-19-20 06:09AM	3 Top Biotech Stocks to Buy Right Now Motley Fool
Dec-18-20 05:45PM	Vertex Pharmaceuticals (VRTX) Stock Moves -0.08%: What You Should Know Zacks
Dec-15-20 07:03AM	Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
Dec-14-20 10:37AM	Billionaire David Shaw Bets Big on These 3 Healthcare Stocks TipRanks
05:51AM	3 Surefire Stocks to Buy When the Stock Market Inevitably Crashes Motley Fool
Dec-13-20 06:45AM	If You Have $1,000 and 5 Years to Wait, Buy These 2 Stocks Now Motley Fool
Dec-12-20 03:39PM	Watch Out bluebird bio, CRISPR Is on Your Heels Motley Fool
Dec-11-20 05:45PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
Dec-10-20 12:47PM	Editas (EDIT) Submits Application to Start Study on EDIT-301 Zacks
Dec-09-20 04:02PM	Top Biotech Stocks for Q1 2021 Investopedia
01:10PM	Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News Zacks
06:09AM	The Best Biotech Stock on the Market Right Now Motley Fool
Dec-08-20 04:45PM	The Latest Lap in Bluebirds and Crisprs Race to Cure Sickle Cell Barrons.com
Dec-07-20 09:19AM	CRISPR (CRSP) Up on Promising Data for Gene Therapy CTX001 Zacks

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Silva Paul M	SVP & Chief Accounting Officer	Mar 01	Sale	211.45	2,782	588,255	9,884	Mar 02 04:07 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 25	Sale	213.39	3,028	646,139	33,589	Feb 26 04:03 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 25	Sale	213.54	3,634	775,989	41,103	Feb 26 04:07 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 25	Sale	213.38	3,028	646,125	30,837	Feb 26 04:18 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 25	Sale	213.42	3,586	765,307	40,133	Feb 26 04:20 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 25	Sale	213.47	1,080	230,552	14,884	Feb 26 04:23 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 18	Sale	211.83	7,825	1,657,590	39,033	Feb 19 04:05 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 18	Sale	211.82	7,825	1,657,481	47,635	Feb 19 04:08 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 18	Sale	211.83	7,825	1,657,556	36,281	Feb 19 04:18 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 18	Sale	211.83	9,264	1,962,366	46,665	Feb 19 04:20 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 18	Sale	211.83	4,295	909,828	16,828	Feb 19 04:21 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 11	Sale	210.54	5,283	1,112,274	53,098	Feb 16 04:02 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 11	Sale	210.55	5,156	1,085,593	61,700	Feb 16 04:07 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 11	Sale	210.56	4,318	909,179	50,346	Feb 16 04:15 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Feb 11	Sale	210.56	1,686	355,012	38,864	Feb 16 04:22 PM
Silva Paul M	SVP & Chief Accounting Officer	Feb 11	Sale	210.57	1,498	315,437	23,863	Feb 16 04:24 PM
Sachdev Amit	EVP, Chief Patient Officer	Feb 11	Sale	210.55	4,460	939,068	63,542	Feb 16 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Option Exercise	86.52	1,930	166,984	59,157	Feb 09 07:44 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 05	Sale	215.00	1,930	414,950	57,227	Feb 09 07:44 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Option Exercise	86.52	1,554	134,452	71,511	Feb 05 04:43 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Option Exercise	86.52	400	34,608	57,627	Feb 05 04:52 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Feb 03	Sale	213.74	1,554	332,146	69,957	Feb 05 04:43 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Feb 03	Sale	216.56	400	86,624	57,227	Feb 05 04:52 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 16	Sale	223.64	7	1,565	35,179	Nov 18 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 16	Sale	223.47	38	8,492	28,902	Nov 18 04:10 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 16	Sale	223.53	91	20,341	26,838	Nov 18 04:12 PM
Sachdev Amit	EVP, Chief Patient Officer	Nov 16	Sale	223.53	42	9,388	35,103	Nov 18 04:16 PM
SACHS BRUCE I	Director	Nov 10	Buy	217.36	15,000	3,260,465	26,210	Nov 12 08:18 AM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Option Exercise	86.52	2,330	201,592	29,168	Nov 06 04:09 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Nov 04	Sale	217.74	2,330	507,329	26,838	Nov 06 04:09 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Option Exercise	86.52	1,553	134,366	36,732	Nov 05 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Nov 03	Sale	211.92	1,553	329,115	35,179	Nov 05 04:16 PM
Bhatia Sangeeta N.	Director	Oct 05	Option Exercise	126.68	8,729	1,105,790	14,424	Oct 07 04:11 PM
Bhatia Sangeeta N.	Director	Oct 05	Sale	266.79	10,516	2,805,518	3,908	Oct 07 04:11 PM
Silva Paul M	SVP & Controller	Aug 06	Option Exercise	169.39	1,078	182,598	16,010	Aug 10 04:24 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Option Exercise	155.57	1,223	190,262	30,125	Aug 10 04:13 PM
Kewalramani Reshma	CEO & President	Aug 06	Option Exercise	179.68	2,073	372,482	28,699	Aug 10 04:19 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Option Exercise	155.57	1,223	190,262	28,061	Aug 10 04:22 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 06	Sale	271.20	1,223	331,672	26,838	Aug 10 04:22 PM
Kewalramani Reshma	CEO & President	Aug 06	Sale	271.20	2,073	562,205	26,626	Aug 10 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 06	Sale	271.19	1,223	331,663	28,902	Aug 10 04:13 PM
Silva Paul M	SVP & Controller	Aug 06	Sale	271.17	1,078	292,319	14,932	Aug 10 04:24 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Option Exercise	86.52	2,330	201,592	31,232	Aug 05 04:14 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Option Exercise	86.52	1,553	134,366	36,732	Aug 05 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Option Exercise	86.52	2,330	201,592	29,168	Aug 05 04:20 PM
Silva Paul M	SVP & Controller	Aug 03	Option Exercise	86.52	809	69,995	15,741	Aug 05 04:24 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Option Exercise	86.52	1,941	167,935	37,044	Aug 05 04:51 PM
Sachdev Amit	EVP, Chief Patient Officer	Aug 03	Sale	278.28	1,941	540,137	35,103	Aug 05 04:51 PM
Silva Paul M	SVP & Controller	Aug 03	Sale	278.30	809	225,142	14,932	Aug 05 04:24 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Aug 03	Sale	278.28	2,330	648,402	26,838	Aug 05 04:20 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Aug 03	Sale	278.39	1,553	432,337	35,179	Aug 05 04:17 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Aug 03	Sale	278.24	2,330	648,290	28,902	Aug 05 04:14 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Jul 13	Option Exercise	90.29	2,125	191,866	28,963	Jul 15 04:41 PM
Silva Paul M	SVP & Controller	Jul 13	Option Exercise	90.29	860	77,649	15,792	Jul 15 04:51 PM
Silva Paul M	SVP & Controller	Jul 13	Sale	292.03	860	251,145	14,932	Jul 15 04:51 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	Jul 13	Sale	292.05	2,125	620,610	26,838	Jul 15 04:41 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Jul 10	Sale	293.15	700	205,206	16,126	Jul 14 04:16 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Jul 07	Option Exercise	173.51	2,786	483,403	37,965	Jul 09 04:13 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	Jul 07	Sale	300.00	2,786	835,800	35,179	Jul 09 04:13 PM
LEIDEN JEFFREY M	Executive Chairman	Jun 30	Sale	286.15	32,792	9,383,304	2,261	Jul 02 04:15 PM
Bhatia Sangeeta N.	Director	Jun 02	Sale	282.88	952	269,298	5,695	Jun 03 04:22 PM
Kewalramani Reshma	CEO & President	May 15	Sale	284.17	99	28,132	26,626	May 19 04:35 PM
Tatsis Ourania	EVP, Chief Regulatory Officer	May 15	Sale	284.00	120	34,080	12,738	May 19 04:33 PM
Silva Paul M	SVP & Controller	May 15	Sale	284.00	151	42,885	14,932	May 19 04:31 PM
Sachdev Amit	EVP, Chief Patient Officer	May 15	Sale	284.41	58	16,496	35,103	May 19 04:29 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 15	Sale	284.40	68	19,339	26,838	May 19 04:28 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	May 15	Sale	283.98	113	32,089	35,179	May 19 04:22 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 15	Sale	284.37	82	23,318	28,902	May 19 04:21 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 12	Option Exercise	187.53	1,304	244,539	30,206	May 14 04:17 PM
LEIDEN JEFFREY M	Executive Chairman	May 12	Option Exercise	137.52	88,532	12,174,639	129,353	May 14 04:19 PM
LEIDEN JEFFREY M	Executive Chairman	May 12	Sale	283.47	94,370	26,751,440	34,983	May 14 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 12	Sale	287.33	1,304	374,678	28,902	May 14 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 11	Option Exercise	187.53	1,304	244,539	28,142	May 13 04:18 PM
Sachdev Amit	EVP, Chief Patient Officer	May 11	Option Exercise	131.89	10,665	1,406,607	45,768	May 13 04:20 PM
Sachdev Amit	EVP, Chief Patient Officer	May 11	Sale	282.61	10,665	3,014,014	35,103	May 13 04:20 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 11	Sale	286.00	1,304	372,944	26,838	May 13 04:18 PM
LEIDEN JEFFREY M	Executive Chairman	May 07	Option Exercise	137.52	88,534	12,174,982	135,190	May 08 04:20 PM
SACHS BRUCE I	Director	May 07	Option Exercise	70.55	45,000	3,174,525	56,210	May 08 04:24 PM
SACHS BRUCE I	Director	May 07	Sale	269.80	45,000	12,140,806	11,210	May 08 04:24 PM
LEIDEN JEFFREY M	Executive Chairman	May 07	Sale	269.78	94,369	25,459,013	40,821	May 08 04:20 PM
Tatsis Ourania	EVP, Chief Regulatory Officer	May 06	Option Exercise	174.06	966	168,146	13,704	May 08 04:28 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 06	Option Exercise	155.57	1,222	190,107	30,124	May 08 04:17 PM
Kewalramani Reshma	CEO & President	May 06	Option Exercise	179.67	2,074	372,638	28,700	May 08 04:19 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 06	Option Exercise	155.57	1,222	190,107	28,060	May 08 04:22 PM
Sachdev Amit	EVP, Chief Patient Officer	May 06	Option Exercise	131.89	669	88,234	35,772	May 08 04:23 PM
Silva Paul M	SVP & Controller	May 06	Option Exercise	169.38	1,076	182,255	16,008	May 08 04:26 PM
Silva Paul M	SVP & Controller	May 06	Sale	272.74	1,076	293,472	14,932	May 08 04:26 PM
Sachdev Amit	EVP, Chief Patient Officer	May 06	Sale	275.28	669	184,162	35,103	May 08 04:23 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 06	Sale	272.64	1,222	333,165	26,838	May 08 04:22 PM
Kewalramani Reshma	CEO & President	May 06	Sale	272.85	2,074	565,882	26,626	May 08 04:19 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 06	Sale	272.66	1,222	333,195	28,902	May 08 04:17 PM
Tatsis Ourania	EVP, Chief Regulatory Officer	May 06	Sale	272.70	966	263,431	12,738	May 08 04:28 PM
Sachdev Amit	EVP, Chief Patient Officer	May 05	Option Exercise	131.89	13,356	1,761,523	48,459	May 06 04:43 PM
LEIDEN JEFFREY M	Executive Chairman	May 05	Option Exercise	137.52	88,537	12,175,273	141,028	May 07 04:24 PM
LEIDEN JEFFREY M	Executive Chairman	May 05	Sale	269.94	94,372	25,475,037	46,656	May 07 04:24 PM
Sachdev Amit	EVP, Chief Patient Officer	May 05	Sale	270.01	13,356	3,606,232	35,103	May 06 04:43 PM
ALTSHULER DAVID	EVP, Global Research and CSO	May 04	Option Exercise	86.52	2,330	201,592	31,232	May 06 04:17 PM
Parini Michael	EVP, Chief Adm, Leg & BD Off	May 04	Option Exercise	86.52	2,330	201,592	29,168	May 06 04:25 PM
Silva Paul M	SVP & Controller	May 04	Option Exercise	86.52	809	69,995	15,741	May 06 04:27 PM
Arbuckle Stuart A	EVP, Chief Commercial Officer	May 04	Option Exercise	86.52	1,553	134,366	36,732	May 06 04:38 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience